Yasmine Kirkorian, MD, Discusses Genetic Clues and Advances in Pediatric Dermatology

In an interview with Dermatology Times, Yasmine Kirkorian, MD, Chief of the Division of Dermatology at Children’s National Hospital and Associate Professor at George Washington University in Washington, DC, shared key insights from her SDPA Fall 2025 sessions on genetic skin disorders and complex pediatric dermatology.

In her first presentation, “The ABC's of Genetic Disorders of the Skin: Guidelines for Recognition and When to Refer,” Kirkorian emphasized the importance of viewing dermatologic findings within the broader developmental context of each patient.¹ She highlighted that growth parameters, such as head circumference and developmental milestones—available through CDC guidelines—can provide valuable clues when considering genetic evaluation. She reminded that children presenting with both cutaneous abnormalities and developmental delays warrant heightened suspicion for underlying genetic syndromes. The session also covered diagnostic approaches to distinct categories of genetic conditions, including those marked by hyperpigmented or hypopigmented lesions, keratinocytic abnormalities, and syndromes associated with increased malignancy risk. Early identification of cancer-predisposing genodermatoses remains a critical goal to ensure appropriate surveillance and timely intervention.

Her pediatric dermatology session, “It's Just a Little Different in Peds,” focused on demystifying complex medical cases, including infectious and reactive conditions.² A major topic was reactive infectious mucocutaneous eruption (RIME), a severe inflammatory condition involving the mucous membranes of the mouth, eyes, or genitals, typically following infection. Kirkorian underscored the importance of early recognition and prompt management to reduce morbidity and hospitalization time for affected children.

Looking ahead, Kirkorian highlighted therapeutic advances for pediatric patients as a major source of excitement in 2025. She noted expanding approvals of nonsteroidal topical therapies for atopic dermatitis, offering new options for moderate cases and reducing reliance on systemic agents. Simultaneously, the extension of systemic biologic and immunomodulatory agents to younger pediatric populations promises to improve outcomes for children with severe inflammatory skin disease.

Finally, Kirkorian discussed initiatives at Children’s National Hospital, including emerging clinical trial programs in alopecia areata, genetic skin disorders, and hidradenitis suppurativa. As fellowship director, she celebrated the approval of a second pediatric dermatology fellowship position, addressing critical workforce shortages and reinforcing the institution’s commitment to training the next generation of pediatric dermatologists.

References

1. Kirkorian, Y. The ABC's of Genetic Disorders of the Skin: Guidelines for Recognition and When to Refer. Presented at: Society of Dermatology Physician Associates Fall 2025 Conference; November 5-9, 2025; San Antonio, Texas.

2. Kirkorian, Y. It's Just a Little Different in Peds: Demystifying Complex Pediatric Dermatology Cases. Presented at: Society of Dermatology Physician Associates Fall 2025 Conference; November 5-9, 2025; San Antonio, Texas.